This Article Full Text (PDF) All Versions of this Article: 1352458508088937v1 14/6/815    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Koch, M Articles by De Keyser, J Search for Related Content PubMed PubMed Citation Articles by Koch, M Articles by De Keyser, J Pubmed/NCBI databases Medline Plus Health Information Depression Social Bookmarking                   What's this?

Fatigue, depression and progression in multiple sclerosis

Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands, m.w.koch{at}neuro.umcg.nl

M Uyttenboogaart

Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands

A van Harten

Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands

M Heerings

Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands

J De Keyser

Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands

Objective

To investigate the effect of fatigue and depression on disease progression in multiple sclerosis (MS), and the long-term prognosis of these symptoms.

Methods

228 patients with MS were investigated for fatigue and depression with the Fatigue Severity Scale (FSS) and Center for Epidemiologic Studies Depression Scale (CES-D). These patients regularly attended the MS clinic, where disability scores and the development of secondary progression were monitored. After 10 years, the 149 patients remaining from the original cohort were asked to participate in a repeat assessment of fatigue and depression and 96 (64%) could be re-evaluated. In relapsing–remitting patients, the influence of baseline fatigue and depression on the risk of secondary progression during the following 10 years was assessed with survival analyses. In the whole patient group, we investigated the influence of baseline fatigue and depression on progression of disability at 10 years. We also investigated differences in fatigue, depression and disability scores between baseline and 10 years.

Results

Fatigue and depression at baseline did not predict the development of secondary progression or progression of disability. Most patients who were fatigued or depressed at baseline remained so at 10 years, and the majority of patients not experiencing these symptoms remained free of them. FSS and CES-D scores were not significantly different between baseline and 10 years, while disability scores significantly increased.

Conclusion

Our data suggest that fatigue and depression in MS are unrelated to disease progression in MS. Fatigue and depression tend to persist at roughly the same levels over time.

Key Words: depression • disability • fatigue • progression

This version was published on July 1, 2008

Multiple Sclerosis, Vol. 14, No. 6, 815-822 (2008)
DOI: 10.1177/1352458508088937


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. F. Foley and D. W. Brandes Redefining functionality and treatment efficacy in multiple sclerosis Neurology, June 9, 2009; 72(23_Supplement_5): S1 - S11. [Abstract] [Full Text] [PDF]